This guidance was commissioned by Janssen-Cilag Ltd as part of an extensive programme of work to support practitioners across the UK to apply best practice to the supervised self-administration of esketamine nasal spray. The document was generated without input from Janssen-Cilag Ltd and the company had no editorial control over the content. Approval prior to publication on the Janssen Medical Cloud was granted following medical (peer) review by Janssen's parent company Johnson and Johnson
